Provenance Record

Clear, well-structured clinical news report (825 words, News category). Sections Overview / What We Know / Regulatory Path / What We Don't Know cleanly separate the verified interim efficacy data from the regulatory path and the explicit surrogate-endpoint caveat. Technical depth is appropriate for a clinical-trial story and every numeric specific is attributed inline to a named outlet.

All 8 source snapshots read from disk by gunzip-ing each source-*.html.gz under sources/2026-06/atacicept-cuts-proteinuria-46-in-phase-3-origin-trial-for-iga-nephropathy-setting-up-a-july-fda-decision/. RULE 9 / RULE 5i CLINICAL VERIFICATION (every statistic traced verbatim to a FETCHABLE, non-403 snapshot): source-1 ccjm.org (HTTP 200) confirms verbatim 45.7% vs 6.8% proteinuria reduction, between-group difference 41.8 pp, P < .001, Gd-IgA1 -68.3% vs -2.9% with reductions by week 4, hematuria resolution 81.0% vs 20.7%, adverse events 59.3% vs 50.0%, 203 patients, atacicept 150 mg SC weekly, ASN Kidney Week 2025 in Houston. source-2 scholars.mssm.edu (HTTP 200) confirms verbatim the geometric mean between-group difference 41.8 pp (95% CI 28.9 to 52.3; P<0.001) AND the full NEJM citation: NEJM Vol. 394, No. 7, pp. 647-657, Published 12 Feb 2026, DOI 10.1056/NEJMoa2510198. source-0 nephjc.com (HTTP 200) confirms the 106-atacicept / 97-placebo split, that serious TEAEs were less frequent with atacicept (0.5% vs 5.1%), and the eGFR-data limitation framing. source-3 stocktitan.net (HTTP 200) confirms the BAFF + APRIL mechanism, the Marshall Fordyce quote verbatim ('We are excited for the potential to deliver the first approved therapy targeting both BAFF and APRIL in adults with IgAN'), and the eGFR-results-Q3-2026 / sBLA-Q4-2026 timing. source-4 pharmacally.com (HTTP 200) confirms the July 7, 2026 PDUFA target action date, Priority Review, Accelerated Approval pathway, BLA acceptance, and 'first B-cell modulator in IgAN to target both BAFF and APRIL'. source-5 ncbi.nlm.nih.gov StatPearls (HTTP 200) confirms ~10% US biopsies, up to 40% East Asia, 20-30% Europe, and 20-50% ESRD within 20 years. source-6 pharmacytimes.com (HTTP 200) confirms sibeprenlimab's November 2025 FDA accelerated approval, Voyxact/Otsuka branding, and first-in-class APRIL inhibitor. source-7 doi.org NEJM (Archive.org fallback, thin wrapper with no article specifics) is cited ONLY for the fact-of-publication, not for any unverifiable statistic — correct usage. NOTE: the task brief flagged NEJM/Vera-IR/HCPLive/Renal&Urology-News as 403; none of those are the cited sources here. The four outlets that quote the paper verbatim (NephJC, CCJM, Mount Sinai, plus StockTitan/Pharmacally/StatPearls/PharmacyTimes) all returned HTTP 200 and were read in full.

No fabricated or misattributed specifics. Every number, name, date, and code traces verbatim to the snapshot it is attributed to. Headline '46%' vs body/summary '45.7%' is an acceptable, consistent rounding — the summary and body both carry the precise 45.7% figure and only the headline rounds. The single direct quote (Fordyce) is verbatim in StockTitan.

High-quality, accurate clinical-trial report. Every clinical statistic and the single quote trace verbatim to a fetchable (HTTP 200) snapshot; the NEJM DOI is correctly used only for fact-of-publication. The sole issue is the source-allowlist warning (chiefly the pharmacally.com aggregator), which the script flags as a warning and which is honestly summarizable in a corrections/provenance note. Verdict: APPROVE_WITH_CORRECTIONS.